Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

NVIDIA

Nvidia Corp. NVDA, +4.72% is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships Monday with Amgen Inc. AMGN, +1.26% and Recursion Pharmaceuticals Inc. RXRX, +3.61%.

Nvidia dives deeper into AI drug development with Amgen, Recursion partnerships

Recursion and NVIDIA will host an invite-only event on Wednesday, January 10, where Recursion will provide live demonstrations of LOWE, its new LLM-based software that can perform complex drug discovery tasks and orchestrate both wet-lab and dry-lab components of the Recursion OS using a natural language interface. Recursion and NVIDIA will host an invite-only event on Wednesday, January 10, where Recursion will provide live demonstrations of LOWE, its new LLM-based software that can perform complex drug discovery tasks and orchestrate both wet-lab and dry-lab components of the Recursion OS using a natural language interface.

Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference

Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Recursion Pharmaceuticals (RXRX) Soars 7.4%: Is Further Upside Left in the Stock?

Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline

Rocket Lab USA

Roku

Cathie Wood bought shares of Roku, Recursion Pharmaceuticals, and Rocket Lab USA on Tuesday. Roku more than doubled in 2023, and momentum is strong heading into 2024.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought in 2024

Denali Therapeutics

Scholar Rock Holding Corp

Americans live longer than ever, and a handful of biotech stocks stand at the forefront of longevity's future. Many misconceive anti-aging stocks as peddling some magic pill that inexplicably makes you live longer — that perception is pure fiction.

3 Biotech Stocks at the Forefront of the Quest for Eternal Youth

Vertex Pharmaceuticals

Zymeworks Inc

On the heels of the devastating COVID-19 pandemic, investor enthusiasm for biotech stocks waned as the Federal Reserve embarked on its aggressive rate-hiking campaign to bring down the red-hot inflation that ensued.

Biotech breakthroughs: Stocks that soared from medical innovations

Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets. Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets.

Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry

CRISPR Therapeutics

Twist Bioscience Corp

Genomics is undeniably medicine's future, and genomics stocks stand to be the next big thing in healthcare as the industry matures. But the crux of the matter is when the industry will mature.

3 Genomics Stocks to Unlock the Future of Medicine

Ginkgo Bioworks Holdings

Cathie Wood's focus on disruptive technologies could be a winning strategy over the long term. Ginkgo Bioworks and Recursion Pharmaceuticals are two of her more intriguing holdings in the biotech industry.

2 Cathie Wood Stocks That Might Be Smart Buys Right Now

AbCellera Biologics

One of the biggest stories of the year has been the rise of AI in every industry. This trend will hit biotech stocks no less than any others.

AI Meets Biotech: 3 Top Stocks Transforming Medical Science

Nvidia will help Recursion build a massive supercomputer. This will be used its for AI-driven drug discovery efforts.

Recursion Pharmaceuticals Wants to 4X Its Supercomputing Power for AI With the Help of Nvidia. Here's Why It Matters.

Aehr Test Systems

AST SpaceMobile

Enovix Corporation

Hims & Hers Health

Finding a great small-cap stock to buy isn't always easy. We know that, over the long run, small-cap stocks as a whole outperform large-cap cousins.

2024's Hidden Gems: 7 Small-Caps Set for Explosive Growth

Recursion Pharmaceuticals has a novel approach to developing drugs. The company has attracted some important collaborations.

This Stock Could Soar by 120%, According to Wall Street

Cathie Wood just massively increased her holdings of Recursion Pharmaceuticals. But the company will probably take a few more years to demonstrate its value.

Cathie Wood Just Made a Big Bet on Recursion Pharmaceuticals Stock. Will It Pay Off?

Recursion Pharmaceuticals, Inc. proof-of-concept data, from the phase 2 SYCAMORE study using REC-994 for the treatment of patients with Cerebral Cavernous Malformation, expected in the 2nd half of 2024. Safety and preliminary efficacy data, from the phase 2/3 POPLAR study using REC-2282 for the treatment of patients with Neurofibromatosis Type 2, expected in the 2nd half of 2024. There are no regulatory-approved drugs to treat either Cerebral Cavernous Malformation or Neurofibromatosis Type 2.

Recursion Pharmaceuticals: Second Half 2024 Data Readouts Are Major Inflection Points

Relay Therapeutics, Inc.

Schrodinger 

We're still in the initial stages of a massively disruptive artificial intelligence ( AI ) boom. Big Tech is investing billions of dollars into it.

AI Alert: 3 Healthcare Stocks That Are Investing in Artificial Intelligence

Bayer AG

BERLIN & SALT LAKE CITY--(BUSINESS WIRE)--Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have updated the focus of their research collaboration to precision oncology. The oncology-focused collaboration will leverage Bayer's small molecule compound library and expertise in biology and medicinal chemistry as well as Recursion's purpose-built artificial intelligence-guided drug discove.

Bayer and Recursion focus research collaboration on Oncology

Digitally enabled drug discovery for oncology has the potential to accelerate the delivery of new cancer therapies to patients. Drug discovery research collaboration may initiate up to seven oncology programs and further strengthens Bayer's early pipeline in precision oncology. Recursion is eligible to receive up to $1.5 billion in potential development and commercial milestone payments plus royalties. Digitally enabled drug discovery for oncology has the potential to accelerate the delivery of new cancer therapies to patients. Drug discovery research collaboration may initiate up to seven oncology programs and further strengthens Bayer's early pipeline in precision oncology. Recursion is eligible to receive up to $1.5 billion in potential development and commercial milestone payments plus royalties.

Bayer and Recursion Focus Research Collaboration on Oncology

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its third quarter ending September 30, 2023.

Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results

SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference:

Recursion to Participate in Upcoming Investor Conference

Archer Aviation

PagerDuty

Roblox

Teradyne

Twilio

In the dynamic world of investing, Cathie Wood stocks continue to draw both bullish advocates and bearish critics. Cathie Wood's Ark Invest isn't your conventional ETF or mutual fund manager.

The 7 Best Cathie Wood Stocks to Buy Now: November Edition

Recursion is forging key relationships with powerful collaborators. The young biotech's valuation is also looking a lot better now.

2 Reasons to Buy Recursion Pharmaceuticals, and 1 Reason to Sell

Anghami

Tilray Brands

Speculative stocks are a risky proposition in today's market. With even the Standard and Practices (S&P) 500's stablest giants dropping, small-cap risky stocks don't stand a chance.

3 Extra-Speculative Stocks That Could Make You Very, Very Rich

News for Recursion Pharmaceuticals Stock (RXRX)